The Case Western Reserve University Cancer Research Center is a multidisciplinary clinical and laboratory research center, combining the resources and expertise at Case Western Reserve University School of Medicine and its major affiliated Hospitals, University Hospitals of Cleveland, MetroHealth Medical Center and the Cleveland Veterans Administration Medical Center. The objectives of the Case Western Reserve University Cancer Research Center are: 1. To improve the prevention, diagnosis and therapy of cancer through rearch; 2. To rapidly develop the clinical applications of research discoveries and to make these applications available to the residents of the northeast Ohio region as quickly as possible; 3. To provide the stimulation and support facilities for the development of coordinated, interdisciplinary cancer research that most effectively utilizes the resources and expertise available at the associated institutions. 4. To provide all the services and benefits of an NIH designated Comprehensive Cancer Center to northeast Ohio and the surrounding region. The goals of the Center are accomplished by activities in 7 active programs, 1 developing program and 8 shared resources. PROGRAMS 1. Molecular Biology of Oncogenesis 2. Molecular Virology and AIDS 3. Hematopoietic and Immune Cell Biology 4. Radiation Biology 5. Environmental Carcinogenesis 6. Tumor Metabolism 7. Clinical Trials 8. Prostate Cancer Biology SHARED RESOURCES 1. Molecular Biology 2. Tissue Culture Support 3. Flow Cytometry 4. Radiation Services 5. Histology 6. Athymic Animal Facility 7. Hematopoietic Stem Cell Facility 8. Biostatistics and Clinical Trial

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-07
Application #
2091234
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1991-09-30
Project End
1996-07-31
Budget Start
1994-08-01
Budget End
1996-07-31
Support Year
7
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726

Showing the most recent 10 out of 1227 publications